Illumina Inc (ILMN) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 28 2026 to Jun 29 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Illumina Inc   (NASDAQ: ILMN)

Illumina Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Illumina Inc in the second quarter 2026?
Illumina Inc achieved a return on average equity (ROE) of 31.08 % in its second quarter 2026, this is above ILMN's average return on equity of 8.62%.
Illumina Inc s equity during the 12 months ending in the second quarter 2026 are valued at $2 billion

ROE fell compared to the first quarter 2026, despite the net income growth of 54.48% from the first quarter 2026.

Within the Laboratory Analytical Instruments industry only one company had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 186 to 324.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 28 2026)
II. Quarter		 (Mar 29 2026)
I. Quarter		 (Dec 28 2025)
IV. Quarter		 (Sep 28 2025)
III. Quarter		 (Jun 29 2025)
II. Quarter
Y / Y Equity Change 25.69 % 13.01 % 14.75 % 12.05 % -
Y / Y Net Income Change -11.91 % 2.29 % 79.57 % -78.72 % -
Net Income (TTM) in Millions 825 853 850 702 1,257
Return On Equity (TTM) 31.08 % 33.99 % 34.94 % 29.94 % 55.11 %
ILMN's Total Ranking # 324 # 186 # 262 # 111 # 80
Equity (TTM) in Millions 2,838 2,676 2,723 2,381 2,258
Seq. Equity Change 6.05 % -1.73 % 14.36 % 5.45 % -4.65 %
Seq. Net Income Change 54.48 % -59.88 % 122.67 % -36.17 % 79.39 %

Back to ILMN Management Effectiveness >> ILMN's 5 Years Annual ROE >> Compare ILMN ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 2
Sector # 55
Overall # 324

Return On Equity Statistics
High Average Low
55.11 %
8.62 %
-64.72 %
(Jun 29 2025)   (Jun 30 2024)





ILMN Annual Return On Equity (Dec 28 2025)
2025		 (Dec 29 2024)
2024		 (Dec 31 2023)
2023		 (Jan 01 2023)
2022		 (Jan 02 2022)
2021
Total Equity in Millions 2,723 2,373 5,745 6,599 10,740
Y / Y Equity Change 14.75 % -58.69 % -12.94 % -38.56 % 128.8 %
Net Income in Millions 850 -1,223 -1,161 -4,404 762
Y / Y Net Income Change - - - - 16.16 %
Return On Equity 31.22 % -51.54 % -20.21 % -66.74 % 7.09 %

Back to ILMN Management Effectiveness >> ILMN's 5 Years Annual ROE >> Compare ILMN ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 31.22 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Laboratory Analytical Instruments Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ILMN's' Return on Equity at Yahoo Finance
ILMN's Roe Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ILMN's Competitors
Subscribers only: Roe for Illumina Inc 's Suppliers
Subscribers only: Return On Equity for ILMN's Customers




Companies with similar Return On Equity at Jun 28 2026, within Healthcare Sector ROE
Q32 Bio Inc   76.88 %
3m Company  76.55 %
Oramed Pharmaceuticals Inc  73.03 %
Tg Therapeutics Inc   72.30 %
Idexx Laboratories Inc  71.96 %
Elite Pharmaceuticals Inc   71.10 %
Zoetis Inc   68.87 %
Rallybio Corporation  68.56 %
Earth Science Tech Inc   66.17 %
Aurinia Pharmaceuticals Inc   59.00 %
Vaxart Inc   53.04 %
Qhslab Inc   51.21 %
Tenet Healthcare Corp  50.64 %
Nrc Health  48.29 %
Concentra Group Holdings Parent Inc   48.13 %
Bristol myers Squibb Company  46.65 %
Agilent Technologies inc   41.99 %
Eton Pharmaceuticals Inc   40.13 %
Adma Biologics Inc   39.59 %
Dexcom Inc   36.25 %
Transmedics Group Inc   33.37 %
Arcutis Biotherapeutics Inc   32.92 %
Caredx Inc   32.81 %
Zevra Therapeutics Inc   32.56 %
Acadia Pharmaceuticals Inc   32.39 %
Pro dex Inc   31.96 %
Protalix Biotherapeutics inc   31.61 %
Illumina Inc   31.08 %
Innoviva Inc   30.03 %
Phibro Animal Health Corporation  29.66 %

Date modified: 2026-09-26T07:13:03+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.